Article Text

Download PDFPDF

Randomised controlled trial
The therapeutic value of hypertonic saline in acute bronchiolitis remains unclear
Free
  1. Jay Pershad
  1. Division of Emergency Medicine, Department of Pediatrics, University of Tennessee Health Science Center and Le Bonheur Children's Hospital, Memphis, Tennessee, USA
  1. Correspondence to: Professor Jay Pershad, Division of Pediatric Emergency Medicine, University of Tennessee Health Science Center and Le Bonheur Children's Hospital, 50 N Dunlap, St. Memphis, TN 38103, USA; jay.pershad{at}mlh.org

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science and OpenUrlCrossRefPubMedWeb of Science

Context

Bronchiolitis is common in children below 2 years of age and is a leading cause of infant hospitalisation, accounting for $1.73 billion in hospital charges in the USA annually.1 The putative effect of hypertonic saline (HTS) in bronchiolitis is to absorb mucosal water, hydrate the airway–surface liquid in the bronchioles and enhance mucociliary clearance.2 However, the therapeutic value of HTS in acute bronchiolitis remains unclear.

Methods

Both randomised controlled trials (RCTs) were conducted in urban, tertiary level, paediatric emergency departments (ED) in the USA. They excluded children with significant comorbidity, and compared the effect of nebulised 3% HTS with normal saline (NS) controls. Both studies used albuterol, given either just prior to or within 90 min of HTS.

Findings

Florin and colleagues enrolled 31 patients in each group, concluding that improvement in Respiratory Assessment Change Score (RACS; primary outcome) 1 h after intervention was less …

View Full Text